Atezolizumab (Tecentriq) Concentrate from Canada
Atezolizumab is a humanized anti-PD-L1 monoclonal for bladder cancer. HTS 3002.15.00.11 for checkpoint immunological product.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Immunotherapy cold chain critical